GigaGen, Inc logo

GigaGen, Inc

GigaGen Inc, is a privately-held, preclinical biopharma company developing novel antibody therapies with robust internal pipeline of novel antibodies against immuno-oncology targets.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.gigagen.com
Founded2010
Disease Focus
Development StagePreclinical
STOCK CODENon Listed
Address
One Tower Pl Suite 750,CA,94080,USA
South San Francisco
United States
Email
Contact Number

In Feb 2017, Trianni and GigaGen entered into a co-discovery contract for immuno-oncology antibody drugs combining Triannis chimeric human mouse for generation of fully human antibodies and GigaGens discovery of antibody therapeutics from millions-diverse immune repertoires.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/gigagen-inc” connections=”true” suffix=””]

GigaGens discovery program, Surge_ Technology, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates, is significantly faster and more comprehensive than conventional hybridoma screening. Utilizing it GigaGen identified more than 2,300 unique monoclonal antibodies against 17 cancer targets: PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, B7-H3, B7-H4, TIGIT, TLR2, TLR4, CSF1R, VISTA, CD47, OX40, GITR, CD27 and ICOS.

In July 2017, Grifols, S.A. acquired 44% stake in GigaGen Inc. for USD 35 Mn in cash. In addition, Grifols and GigaGen entered into research collaboration agreement whereby, in exchange of a collaboration fee of USD 15 Mn in the aggregate, GigaGen will commit to carry out research activities to develop recombinant polyclonal immunoglobulin therapies derived from human B cells for the treatment of human diseases.